Literature DB >> 19950170

c-Rel phenocopies PKCtheta but not Bcl-10 in regulating CD8+ T-cell activation versus tolerance.

Elissa K Deenick1, Leslie Po, Laurence Chapatte, Kiichi Murakami, Yong-Chen Lu, Alisha R Elford, Samuel D Saibil, Jürgen Ruland, Steve Gerondakis, Tak W Mak, Pamela S Ohashi.   

Abstract

Elucidating the signaling events that promote T-cell tolerance versus activation provides important insights for manipulating immunity in vivo. Previous studies have suggested that the absence of PKCtheta results in the induction of anergy and that the balance between the induction of the transcription factors NFAT, AP1 and NF-kappaB plays a key role in determining whether T-cell anergy or activation is induced. Here, we examine whether Bcl-10 and specific family members of NF-kappaB act downstream of PKCtheta to alter CD8(+) T-cell activation and/or anergy. We showed that T cells from mice deficient in c-Rel but not NF-kappaB1 (p50) have increased susceptibility to the induction of anergy, similar to T cells from PKCtheta-deficient mice. Surprisingly T cells from Bcl-10-deficient mice showed a strikingly different phenotype to the PKCtheta-deficient T cells, with a severe block in TCR-mediated activation. Furthermore, we have also shown that survival signals downstream of NF-kappaB, are uncoupled from signals that mediate T-cell anergy. These results suggest that c-Rel plays a critical role downstream of PKCtheta in controlling CD8(+) T-cell anergy induction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19950170     DOI: 10.1002/eji.200939445

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

Review 1.  Peli: a family of signal-responsive E3 ubiquitin ligases mediating TLR signaling and T-cell tolerance.

Authors:  Wei Jin; Mikyoung Chang; Shao-Cong Sun
Journal:  Cell Mol Immunol       Date:  2012-02-06       Impact factor: 11.530

2.  The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.

Authors:  Marilyn Giordano; Romain Roncagalli; Pierre Bourdely; Lionel Chasson; Michel Buferne; Sho Yamasaki; Rudi Beyaert; Geert van Loo; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst; Grégory Verdeil
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

3.  The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity.

Authors:  Mikyoung Chang; Wei Jin; Jae-Hoon Chang; Yichuan Xiao; George C Brittain; Jiayi Yu; Xiaofei Zhou; Yi-Hong Wang; Xuhong Cheng; Pingwei Li; Brian A Rabinovich; Patrick Hwu; Shao-Cong Sun
Journal:  Nat Immunol       Date:  2011-08-28       Impact factor: 25.606

Review 4.  Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy.

Authors:  Simone Nüssing; Joseph A Trapani; Ian A Parish
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

Review 5.  NF-κB in Cancer Immunity: Friend or Foe?

Authors:  Guilhem Lalle; Julie Twardowski; Yenkel Grinberg-Bleyer
Journal:  Cells       Date:  2021-02-09       Impact factor: 6.600

6.  Protein kinase C signaling and cell cycle regulation.

Authors:  Adrian R Black; Jennifer D Black
Journal:  Front Immunol       Date:  2013-01-17       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.